MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, TPST had -$22,561K decrease in cash & cash equivalents over the period. -$26,820K in free cash flow.

Cash Flow Overview

Change in Cash
-$22,561K
Free Cash flow
-$26,820K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from the issuance of co...
    • Proceeds from the issuance of pr...
    • Proceeds from the issuance of co...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Repayment of loan
    • Accrued expenses and other liabi...
    • Others

Cash Flow
2025-12-31
Net loss
-26,262
Depreciation expense
266
Stock-based compensation expense
3,118
Noncash lease expense
1,103
Noncash interest and other expense, net
85
Prepaid expenses and other assets
-615
Accounts payable
-1,412
Accrued expenses and other liabilities
-3,404
Interest payable
-59
Operating lease liabilities
-870
Cash used in operating activities
-26,820
Purchase of property and equipment
0
Cash used in investing activities
0
Proceeds from the issuance of common stock, net of issuance costs
6,045
Proceeds from the issuance of pre-funded warrants, net of issuance costs
3,309
Proceeds from the issuance of common stock warrants, net of issuance costs
1,284
Repayment of loan
6,426
Proceeds from the issuance of common stock under equity plan awards
47
Cash provided by financing activities
4,259
Net increase in cash and cash equivalents
-22,561
Cash, cash equivalents and restricted cash at beginning of period
30,711
Cash, cash equivalents and restricted cash at end of period
8,150
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from theissuance of common stock,...$6,045K Proceeds from theissuance of pre-funded...$3,309K Proceeds from theissuance of common stock...$1,284K Proceeds from theissuance of common stock...$47K Cash provided byfinancing activities$4,259K Canceled cashflow$6,426K Net increase in cashand cash...-$22,561K Canceled cashflow$4,259K Stock-based compensationexpense$3,118K Noncash lease expense$1,103K Prepaid expenses andother assets-$615K Depreciation expense$266K Noncash interest andother expense, net$85K Repayment of loan$6,426K Cash used inoperating activities-$26,820K Canceled cashflow$5,187K Net loss-$26,262K Accrued expenses andother liabilities-$3,404K Accounts payable-$1,412K Operating leaseliabilities-$870K Interest payable-$59K

Tempest Therapeutics, Inc. (TPST)

Tempest Therapeutics, Inc. (TPST)